Status: Currently Official on 14-Feb-2025
Official Date: Official as of 01-Dec-2016
Document Type: USP Monographs
DocId: GUID-48A3C9EC-BE00-44D8-9430-9C7ADCCF070F\_1\_en-US
DOI: https://doi.org/10.31003/USPNF\_M19670\_01\_01
DOI Ref: 14ixx

© 2025 USPC Do not distribute

# **Codeine Sulfate Tablets**

# **DEFINITION**

Codeine Sulfate Tablets contain NLT 93.0% and NMT 107.0% of the labeled amount of codeine sulfate trihydrate [(C<sub>19</sub>H<sub>21</sub>NO<sub>2</sub>)<sub>2</sub> · H<sub>2</sub>SO<sub>3</sub> · 3H<sub>2</sub>O].

#### IDENTIFICATION

- A. The retention time of the major peak of the Sample solution corresponds to that of the Standard solution, as obtained in the Assay.
- B.

**Standard solution** and **Sample solution**: Proceed as directed in the *Assay*.

Analysis: Inject 2 µL each of the Standard solution and the Sample solution using the Chromatographic system in the Assay.

**Acceptance criteria:** The spectrum of the codeine peak of the *Sample solution* exhibits maxima and minima at the same wavelengths as those of the corresponding peaks of the *Standard solution*, as obtained in the *Assay*.

### **ASSAY**

• PROCEDURE

Solution A: Acetonitrile and 0.1% ammonium hydroxide (1.0 mL of concentrated ammonium hydroxide and 1000 mL of water) (1:19)

Solution B: Acetonitrile and 0.1% ammonium hydroxide (9:11)

Mobile phase: See Table 1.

Table 1

Time (min)	Solution A (%)	Solution B (%)
0	100	0
40	0	100
41	100	0
50	100	0

[Note—The Standard solution and Sample solution, for the degradation products, are stable for 4 days when stored at room temperature in amber vials.]

Diluent: 0.5% phosphoric acid (5 mL of concentrated phosphoric acid and 1000 mL of water)

**Standard solution:** 1.2 mg/mL of <u>USP Codeine Sulfate RS</u> in *Diluent* 

**Sample solution:** Nominally 1.2 mg/mL of codeine sulfate trihydrate in *Diluent*. Dissolve 20 Tablets in 80% of the flask volume of *Diluent* and sonicate for 15–30 min with occasional swirling before diluting with *Diluent* to volume.

# **Chromatographic system**

(See Chromatography (621), System Suitability.)

Mode: LC

**Detector:** UV 282 nm. For *Identification* test *B*, use a diode-array detector in the range of 210–400 nm.

Column: 4.6-mm × 15-cm; 3-µm packing L1

Column temperature: 40° Flow rate: 1.2 mL/min Injection volume: 40 µL

**System suitability** 

Sample: Standard solution

# https://trumgtamthuoc.com/

Suitability requirements

Tailing factor: NMT 2.0

Relative standard deviation: NMT 2.0%

**Analysis** 

Samples: Standard solution and Sample solution

Calculate the percentage of the labeled amount of codeine sulfate trihydrate  $[(C_{18}H_{21}NO_3)_2 \cdot H_2SO_4 \cdot 3H_2O]$  in the portion of Tablets taken:

Result = 
$$(r_{11}/r_{s}) \times (C_{s}/C_{11}) \times (M_{r1}/M_{r2}) \times 100$$

 $r_{ij}$  = peak area of codeine sulfate from the Sample solution

 $r_s$  = peak area of codeine sulfate from the Standard solution

C<sub>s</sub> = concentration of <u>USP Codeine Sulfate RS</u> in the Standard solution (mg/mL)

C<sub>11</sub> = nominal concentration of codeine sulfate trihydrate in the Sample solution (mg/mL)

 $M_{r_1}$  = molecular weight of codeine sulfate trihydrate, 750.85

 $M_{c2}$  = molecular weight of codeine sulfate, anhydrous, 696.81

Acceptance criteria: 93.0%-107.0%

# **PERFORMANCE TESTS**

• DISSOLUTION (711)

**Medium:** Water; 500 mL **Apparatus 2:** 25 rpm

Time: 45 min

Detector: UV maxima at about 284 nm

Cell: 1 cm Blank: Medium

Standard solution: USP Codeine Sulfate RS in Medium

Sample solution: Pass a portion of the solution under test through a suitable filter of 0.8-µm pore size.

**Tolerances:** NLT 75% (Q) of the labeled amount of codeine sulfate trihydrate  $[(C_{18}H_{21}NO_3)_2 \cdot H_2SO_4 \cdot 3H_2O]$  is dissolved.

• UNIFORMITY OF DOSAGE UNITS (905): Meet the requirements

# **IMPURITIES**

• ORGANIC IMPURITIES

**Solution A, Solution B, Mobile phase, Diluent, Standard solution, Sample solution,** and **Chromatographic system:** Proceed as directed in the *Assay*.

Sensitivity solution: 0.6 µg/mL of USP Codeine Sulfate RS from the Standard solution in Diluent

**System suitability** 

Samples: Standard solution and Sensitivity solution

Suitability requirements

Tailing factor: NMT 2.0, Standard solution

Relative standard deviation: NMT 2.0%, Standard solution

Signal-to-noise ratio: NLT 10, Sensitivity solution

**Analysis** 

Samples: Standard solution and Sample solution

Calculate the percentage of each individual impurity in the portion of Tablets taken:

Result = 
$$(r_{ij}/r_{s}) \times (C_{s}/C_{ij}) \times (1/F) \times 100$$

 $r_{ij}$  = peak response of each individual impurity from the Sample solution

 $r_{\rm s}$  = peak response of codeine sulfate from the Standard solution

 $C_s$  = concentration of <u>USP Codeine Sulfate RS</u> in the Standard solution (mg/mL)

 $C_{_{IJ}}$  = nominal concentration of codeine sulfate trihydrate in the Sample solution (mg/mL)

F = relative response factor (see <u>Table 2</u>)

Acceptance criteria: See <u>Table 2</u>. Disregard any impurity peak less than 0.05%.

Table 2

Name	Relative Retention Time	Relative Response Factor	Acceptance Criteria, NMT (%)
Codeine- <i>N</i> -oxide <sup>a</sup>	0.39	1.25	0.2
Codeine sulfate	1.00	-	-
Codeinone <sup>b</sup>	1.10	1.0	0.3
Individual unspecified degradant	_	1.0	0.2
Total impurities	_	-	0.5

<sup>&</sup>lt;sup>a</sup> 7,8-Didehydro-4,5 $\alpha$ -epoxy-3-methoxy-17-methylmorphinan-6 $\alpha$ -ol *N*-oxide.

# **ADDITIONAL REQUIREMENTS**

- PACKAGING AND STORAGE: Preserve in well-closed containers. Store at controlled room temperature. Protect from moisture and light.
- USP REFERENCE STANDARDS (11) USP Codeine Sulfate RS

 $\textbf{Auxiliary Information} \text{ - Please } \underline{\text{check for your question in the FAQs}} \text{ before contacting USP.}$ 

Topic/Question	Contact	Expert Committee
CODEINE SULFATE TABLETS	Documentary Standards Support	SM22020 Small Molecules 2

Chromatographic Database Information: Chromatographic Database

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 41(5)

Current DocID: GUID-48A3C9EC-BE00-44D8-9430-9C7ADCCF070F\_1\_en-US

DOI: https://doi.org/10.31003/USPNF\_M19670\_01\_01

DOI ref: 14ixx

 $<sup>^{</sup>b}$  7,8-Didehydro-4,5 $\alpha$ -epoxy-3-methoxy-17-methylmorphinan-6 $\alpha$ -one.